Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Galena Biopharma Inc    GALE   US3632561086

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/18/2014 11/19/2014 11/20/2014 11/21/2014 11/24/2014 Date
1.84(c) 1.81(c) 1.86(c) 2.07(c) 2.0541 Last
570 047 672 296 799 063 4 935 323 701 236 Volume
+1.66% -1.63% +2.76% +11.29% -0.77% Change
More quotes
Company
Galena Biopharma, Inc. is a biotechnology company focused on discovering, developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care.It currently develops peptide antigenbased off the shelf cancer immunotherapies for... 
Surperformance© rating of Galena Biopharma Inc
Trading Rating : Investor Rating :
More about the company
Chart GALENA BIOPHARMA INC
Duration : Period :
Galena Biopharma Inc Technical Analysis Chart | GALE | US3632561086 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 8,70 M
EBIT 2014 -53,2 M
Net income 2014 -44,5 M
Debt 2014 -
Yield 2014 -
Sales 2015 19,0 M
EBIT 2015 -40,4 M
Net income 2015 -40,0 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 28,9x
Capi. / Sales 2015 13,3x
Capitalization 251 M
More Financials
Latest news on GALENA BIOPHARMA INC
4d ago GALENA BIOPHARMA : Entry into a Material Definitive Agreement, Financial Stateme..
4d ago GALENA BIOPHARMA : Announces Purchase Agreement for Up to $55.0 Million With Lin..
6d ago GALENA BIOPHARMA : Completes Enrollment in GALE-401 (Anagrelide Controlled Relea..
11/13 GALENA BIOPHARMA : to Present at the Stifel 2014 Healthcare Conference
11/11 GALENA BIOPHARMA : Doses First Patient in Phase 2 Clinical Trial With NeuVax(TM)..
11/07 GALENA BIOPHARMA : Change in Directors or Principal Officers (form 8-K)
11/07 GALENA BIOPHARMA : Presents GALE-301 (Folate Binding Protein Immunotherapy) Phas..
11/05 GALENA BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
11/04 GALENA BIOPHARMA : to Present GALE-301 (Folate Binding Protein) Phase 2a Clinica..
11/03 GALENA BIOPHARMA : beats 3Q profit forecasts
11/03 GALENA BIOPHARMA : Results of Operations and Financial Condition, Financial Stat..
11/03 GALENA BIOPHARMA : Reports Third Quarter 2014 Results
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF